Zurich Cantonal Bank’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-7,368
| Closed | -$283K | – | 2820 |
|
|
2023
Q2 | $283K | Buy |
7,368
+1,527
| +26% | +$39.2K | ﹤0.01% | 1703 |
|
|
2023
Q1 | $135K | Sell |
5,841
-484
| -8% | -$11.5K | ﹤0.01% | 2108 |
|
|
2022
Q4 | $166K | Sell |
6,325
-2,258
| -26% | -$50K | ﹤0.01% | 1936 |
|
|
2022
Q3 | $169K | Buy |
8,583
+6,836
| +391% | +$137K | ﹤0.01% | 1851 |
|
|
2022
Q2 | $31K | Sell |
1,747
-176
| -9% | -$2.76K | ﹤0.01% | 2719 |
|
|
2022
Q1 | $31K | Buy |
+1,923
| New | +$26.1K | ﹤0.01% | 2607 |
|
|
2019
Q4 | – | Sell |
-290
| Closed | -$2K | – | 2638 |
|
|
2019
Q3 | $2K | Hold |
290
| – | – | ﹤0.01% | 2609 |
|
|
2019
Q2 | $2K | Sell |
290
-1,040
| -78% | -$15.8K | ﹤0.01% | 2610 |
|
|
2019
Q1 | $26K | Sell |
1,330
-1,150
| -46% | -$20.1K | ﹤0.01% | 2335 |
|
|
2018
Q4 | $33K | Buy |
2,480
+1,440
| +138% | +$28.8K | ﹤0.01% | 2260 |
|
|
2018
Q3 | $38K | Hold |
1,040
| – | – | ﹤0.01% | 2289 |
|
|
2018
Q2 | $36K | Hold |
1,040
| – | – | ﹤0.01% | 2292 |
|
|
2018
Q1 | $48K | Sell |
1,040
-400
| -28% | -$14.6K | ﹤0.01% | 2100 |
|
|
2017
Q4 | $54K | Hold |
1,440
| – | – | ﹤0.01% | 2017 |
|
|
2017
Q3 | $77K | Buy |
+1,440
| New | +$85.6K | ﹤0.01% | 1543 |
|
|
2017
Q2 | – | Sell |
-1,105
| Closed | -$59K | – | 2578 |
|
|
2017
Q1 | $59K | Buy |
1,105
+425
| +63% | +$24K | ﹤0.01% | 1655 |
|
|
2016
Q4 | $39K | Hold |
680
| – | – | ﹤0.01% | 1868 |
|
|
2016
Q3 | $42K | Buy |
+680
| New | +$48.1K | ﹤0.01% | 1758 |
|
Zurich Cantonal Bank's KDNY Position: Q3 2023 in Review
Zurich Cantonal Bank sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 7,368 shares — an estimated $283K sold.
Zurich Cantonal Bank first reported a position in KDNY in Q3 2016 and held it in 18 quarters. The position peaked at $283K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Zurich Cantonal Bank reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Zurich Cantonal Bank sold 7,368 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $283K.
- Zurich Cantonal Bank first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2016 and held it in 18 quarters.
- Zurich Cantonal Bank's Chinook Therapeutics, Inc. Common Stock position peaked at $283K in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Zurich Cantonal Bank's 13F filing for Q3 2023, filed 25 Oct 2023.